The link between altered cholesterol metabolism and Alzheimer's disease

Annals of the New York Academy of Sciences

Volumn 1259, Issue 1, 2012, Pages 54-64

  Gamba, Paola ^a   Testa, Gabriella ^a   Sottero, Barbara ^a   Gargiulo, Simona ^a   Poli, Giuseppe ^a   Leonarduzzi, Gabriella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Alzheimer's disease; Amyloid ; Cholesterol; Neurotoxicity; Oxidative stress; Oxysterols

Indexed keywords

24 HYDROXYCHOLESTEROL; 26 HYDROXYCHOLESTEROL; 7BETA HYDROXYCHOLESTEROL; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL DERIVATIVE; OXYSTEROL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CHOLESTEROL METABOLISM; DISEASE ASSOCIATION; HUMAN; NEUROPATHOLOGY; NEUROTOXICITY;

EID: 84863510126     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06513.x     Document Type: Article

References (105)

1. Querfurth, H.W. & F.M. LaFerla 2010. Alzheimer's disease. N. Engl. J. Med. 362: 329-344.
2. Chopra, K., S. Misra & A. Kuhad 2011. Neurobiological aspects of Alzheimer's disease. Expert. Opin. Ther. Targets 15: 535-555.
3. Walsh, D.M. & D.J. Selkoe 2007. A beta oligomers-a decade of discovery. J. Neurochem. 101: 1172-1184.
4. Martins, I.J. et al 2009. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J. Neurochem. 111: 1275-1308.
5. Carter, C.J. 2007. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem. Int. 50: 12-38.
6. Wollmer, M.A. 2010. Cholesterol-related genes in Alzheimer's disease. Biochim. Biophys. Acta 1801: 762-773.
7. Ghribi, O. 2008. Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. J. Alzheimers Dis. 15: 673-684.
8. Di Paolo, G. & T.W. Kim 2011. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat. Rev. Neurosci. 12: 284-296.
9. Shobab, L.A., G.Y. Hsiung & H.H. Feldman 2005. Cholesterol in Alzheimer's disease. Lancet Neurol. 4: 841-852.
10. Panza, F. et al 2006. Lipid metabolism in cognitive decline and dementia. Brain Res. Rev. 51: 275-292.
11. Pappolla, M.A. et al 2003. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61: 199-205.
12. Jick, H. et al 2000. Statins and the risk of dementia. Lancet 356: 1627-1631.
13. Wolozin, B. et al 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57: 1439-1443.
14. Zamrini, E., G. McGwin & J.M. Roseman 2004. Association between statin use and Alzheimer's disease. Neuroepidemiology 23: 94-98.
15. Kandiah, N. & H.H. Feldman 2009. Therapeutic potential of statins in Alzheimer's disease. J. Neurol. Sci. 283: 230-234.
16. Fonseca, A.C. et al 2010. Cholesterol and statins in Alzheimer's disease: current controversies. Exp. Neurol. 223: 282-293.
17. Arvanitakis, Z. et al 2008. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70: 1795-1802.
18. Puglielli, L., R.E. Tanzi & D.M. Kovacs 2003. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6: 345-351.
19. Evans, R.M. et al 2004. Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 62: 1879-1881.
20. Bu, G. 2009. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10: 333-344.
21. Kim, J., J.M. Basak & D.M. Holtzman 2009. The role of apolipoprotein E in Alzheimer's disease. Neuron 63: 287-303.
22. Marzolo, M.P. & G. Bu 2009. Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. Semin. Cell. Dev. Biol. 20: 191-200.
23. Jiang, Q. et al 2008. ApoE promotes the proteolytic degradation of Abeta. Neuron 58: 681-693.
24. Sagare, A. et al 2007. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 13: 1029-1031.
25. Cam, J.A. & G. Bu 2006. Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol. Neurodegener. 18: 1-8.
26. Herz, J. & U. Beffert 2000. Apolipoprotein E receptors: linking brain development and Alzheimer's disease. Nat. Rev. Neurosci. 1: 51-58.
27. Liu, Q. et al 2007. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56: 66-78.
28. Jenner, A.M. et al 2010. The effect of APOE genotype on brain levels of oxysterols in young and old human APOE epsilon2, epsilon3 and epsilon4 knock-in mice. Neuroscience 169: 109-115.
29. Pfrieger, F.W. 2003. Cholesterol homeostasis and function in neurons of the central nervous system. Cell. Mol. Life Sci. 60: 1158-1171.
30. Björkhem, I. & S. Meaney 2004. Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24: 806-815.
31. Pfrieger, F.W. 2003. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays 25: 72-78.
32. Cordy, J.M., N.M. Hooper & A.J. Turner 2006. The involvement of lipid rafts in Alzheimer's disease. Mol. Membr. Biol. 23: 111-122.
33. Vetrivel, K.S. & G. Thinakaran 2010. Membrane rafts in Alzheimer's disease beta-amyloid production. Biochim. Biophys. Acta 1801: 860-867.
34. Beel, A.J. et al 2010. Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid-Alzheimer's disease relationships? Biochim. Biophys. Acta 1801: 975-982.
35. Wahrle, S. et al 2002. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9: 11-23.
36. Hur, J.Y. et al 2008. Active gamma-secretase is localized to detergent-resistant membranes in human brain. FEBS J. 275: 1174-1187.
37. Grimm, M.O. et al 2008. Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels. J. Biol. Chem. 283: 11302-11311.
38. Xiong, H. et al 2008. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol. Dis. 29: 422-437.
39. Reid, P.C. et al 2007. Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J. Cell. Mol. Med. 11: 383-392.
40. Harris, B., I. Pereira & E. Parkin 2009. Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein. Brain Res. 1296: 203-215.
41. Yanagisawa, K. 2005. Cholesterol and amyloid beta fibrillogenesis. Subcell. Biochem. 38: 179-202.
42. Kakio, A. et al 2002. Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41: 7385-7390.
43. Harris, J.R. 2008. Cholesterol binding to amyloid-beta fibrils: a TEM study. Micron 9: 1192-1196.
44. Kakio, A. et al 2001. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 276: 24985-24990.
45. Burns, M.P. et al 2006. Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice. Neuromolecular Med. 8: 319-328.
46. Puglielli, L. et al 2001. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3: 905-912.
47. Bhattacharyya, R. & D.M. Kovacs 2010. ACAT inhibition and amyloid beta reduction. Biochim. Biophys. Acta 1801: 960-965.
48. Michikawa, M. et al 2001. A novel action of alzheimer's amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release. Neurosci. 21: 7226-7235.
49. Gong, J.S. et al 2002. Amyloid beta-protein affects cholesterol metabolism in cultured neurons: implications for pivotal role of cholesterol in the amyloid cascade. J. Neurosci. Res. 70: 438-446.
50. Fan, Q.W. et al 2001. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J. Neurochem. 76: 391-400.
51. Koudinov, A.R. & N.V. Koudinova 2005. Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. J. Neurol. Sci. 229-230: 233-240.
52. Mori, T. et al 2001. Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J. Neuropathol. Exp. Neurol. 60: 778-785.
53. Burns, M.P. et al 2003. Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Brain Res. Mol. Brain Res. 110: 119-125.
54. Björkhem, I. et al 2009. Oxysterols and neurodegenerative diseases. Mol. Aspects Med. 30: 171-179.
55. Björkhem I. 2006. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J. Intern. Med. 260: 493-508.
56. Abildayeva, K. et al 2006. 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J. Biol. Chem. 281: 12799-12808.
57. Meaney, S. et al 2007. Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7alpha-hydroxy-3-oxo-4-cholestenoic acid. J. Lipid Res. 48: 944-951.
58. Heverin, M. et al 2005. Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J. Lipid Res. 46: 1047-1052.
59. Nelson, T.J. & D.L. Alkon 2005. Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J. Biol. Chem. 280: 7377-7387.
60. Lütjohann, D. et al 2000. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J. Lipid Res. 41: 195-198.
61. Papassotiropoulos, A. et al 2002. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36: 27-32.
62. Kölsch, H. et al 2004. Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci. Lett. 368: 303-308.
63. Bretillon, L. et al 2000. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci. Lett. 293: 87-90.
64. Bogdanovic, N. et al 2001. On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci. Lett. Nov. 314: 45-48.
65. Brown, J. 3rd et al 2004. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J. Biol. Chem. 13: 34674-34681.
66. Iuliano, L. et al 2010. Vitamin E and enzymatic/oxidative stress-driven oxysterols in amnestic mild cognitive impairment subtypes and Alzheimer's disease. J. Alzheimers Dis. 21: 1383-1392.
67. Heverin, M. et al 2004. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J. Lipid Res. 45: 186-193.
68. Shafaati, M. et al 2011. Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation. J. Lipid Res. 52: 1004-1010.
69. Björkhem, I. et al 2006. Oxysterols and Alzheimer's disease. Acta Neurol. Scand. Suppl. 185: 43-49.
70. Leoni, V. et al 2003. Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. J. Lipid Res. 44: 793-799.
71. Yau, J.L. et al 2003. Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer's disease. Neuroscience 121: 307-314.
72. Leoni, V. et al 2004. Diagnostic use of cerebral and extracerebral oxysterols. Clin. Chem. Lab. Med. 42: 186-191.
73. Kim, W.S. et al 2009. Impact of 27-hydroxycholesterol on amyloid-beta peptide production and ATP-binding cassette transporter expression in primary human neurons. J. Alzheimers Dis. 16: 121-131.
74. Wang, L. et al 2002. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc. Natl. Acad. Sci. USA 15: 13878-13883.
75. Riddell, D.R. et al 2007. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 34: 621-628.
76. Zelcer, N. et al 2007. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc. Natl. Acad. Sci. USA 19: 10601-10606.
77. Cao, G. et al 2007. Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. Curr. Alzheimer Res. 4: 179-184.
78. Famer, D. et al 2007. Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem. Biophys. Res. Commun. 359: 46-50.
79. Prasanthi, J.R. et al 2009. Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol. Neurodegener. 4: 1-8.
80. Marwarha, G. et al 2010. Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J. Alzheimers Dis. 19: 1007-1019.
81. Sharma, S. et al 2008. Hypercholesterolemia-induced Abeta accumulation in rabbit brain is associated with alteration in IGF-1 signaling. Neurobiol. Dis. 32: 426-432.
82. Mateos, L. et al 2009. Activity-regulated cytoskeleton-associated protein in rodent brain is down-regulated by high fat diet in vivo and by 27-hydroxycholesterol in vitro. Brain Pathol. 19: 69-80.
83. Akiyama, H. et al 2000. Inflammation and Alzheimer's disease. Neurobiol. Aging 21: 383-421.
84. Guglielmotto, M. et al 2010. Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front. Aging Neurosci. 2: 1-8.
85. Khandelwal, P.J., A.M. Herman & C.E. Moussa 2011. Inflammation in the early stages of neurodegenerative pathology. J. Neuroimmunol. 15: 1-11.
86. Sastre, M. et al 2011. Inflammatory risk factors and pathologies associated with Alzheimer's disease. Curr. Alzheimer Res. 8: 132-141.
87. Ferretti, M.T. & A.C. Cuello 2011. Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? Curr. Alzheimer Res. 8: 164-174.
88. Verdier, Y., M. Zarándi & B. Penke 2004. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J. Pept. Sci. 10: 229-248.
89. Schwab, C. & P.L. McGeer 2008. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J. Alzheimers Dis. 13: 359-369.
90. Abbas, N. et al 2002. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J. Neuroimmunol. 126: 50-57.
91. Nunomura, A. et al 2001. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60: 759-767.
92. Zhu, X. et al 2007. Causes of oxidative stress in Alzheimer disease. Cell. Mol. Life Sci. 64: 2202-2210.
93. Smith, M.A. et al 2010. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J. Alzheimers Dis. 19: 363-372.
94. Bonda, D.J. et al 2010. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology 59: 290-294.
95. Ding, Q., E. Dimayuga & J.N. Keller 2007. Oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease. Curr. Alzheimer Res. 4: 73-79.
96. Praticò, D. et al 2001. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21: 4183-4187.
97. Naylor, R., A.F. Hill & K.J. Barnham 2008. Neurotoxicity in Alzheimer's disease: is covalently crosslinked A beta responsible? Eur. Biophys. J. 37: 265-268.
98. Arca, M. et al 2007. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy. Free Radic. Biol. Med. 42: 698-705.
99. Melov, S. et al 2007. Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One 2: e536.
100. Cassano, T. et al 2011. Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease. Neurobiol. Aging 27. doi:
101. Usui, K. et al 2009. Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. Proc. Natl. Acad. Sci. USA 106: 18563-18568.
102. Kolsch, H. et al 2000. 7alpha-Hydroperoxycholesterol causes CNS neuronal cell death. Neurochem. Int. 36: 507-512.
103. Ong, W.Y. et al 2010. Changes in brain cholesterol metabolome after excitotoxicity. Mol. Neurobiol. 41: 299-313.
104. Ferrera, P. et al 2008. Cholesterol potentiates beta-amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress. Neurochem. Res. 33: 1509-1517.
105. Gamba, P. et al 2011. Interaction between 24-hydroxycholesterol, oxidative stress, and amyloid-β in amplifying neuronal damage in Alzheimer's disease: three partners in crime. Aging Cell 10: 403-417.